

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

John S. PATTON et al.

APPLICATION No.: 10/612,376

FILED: July 1, 2003

FOR: METHODS AND COMPOSITIONS FOR PULMONARY
DELIVERY OF INSULIN (AS AMENDED)

EXAMINER: Gollamudi S. KISHORE

ART UNIT: 1612

CONF. No.: 3703

REQUEST FOR CORRECTED FILING RECEIPT

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants attach a copy of the official Filing Receipt received from the United States Patent and Trademark Office in the above-referenced application and respectfully request a corrected filing receipt incorporating the following change:

Title

Please correct the title of the application to read as follows:
Methods and Compositions for ~~the~~ Pulmonary Delivery of Insulin

The requested change is also reflected on the enclosed marked-up copy of the official Filing Receipt. It is believed that no fees are due for timely consideration of this paper. In the event that any fees are required, the Commissioner is hereby authorized and requested to charge Deposit Account No. 50-0348.

Respectfully submitted,
Nektar Therapeutics

Date: 03 Nov 08


Steven J. Helmer
Registration No. 40,475

CORRESPONDENCE ADDRESS:
Customer No. 21968

Tele. (650) 631-3100 / Fax: (650) 620-6395

COPY



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER OF PATENTS AND TRADEMARKS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/612,376	07/01/2003	1616	834	0005.15	8	18	4

CONFIRMATION NO. 3703

FILING RECEIPT



OC000000010934834

21968
 NEKTAR THERAPEUTICS
 150 INDUSTRIAL ROAD
 SAN CARLOS, CA 94070

Date Mailed: 09/26/2003

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

John S. Patton, Portola Valley, CA;
 Linda S. Foster, Sunnyvale, CA;
 Robert M. Platz, Half Moon Bay, CA;

Domestic Priority data as claimed by applicant

This application is a CON of 08/668,036 06/17/1996
 which is a DIV of 08/383,475 02/01/1995 ABN
 which is a CIP of 08/207,472 03/07/1994 ABN


Foreign Applications

If Required, Foreign Filing License Granted: 09/26/2003

Projected Publication Date: 01/08/2004

Non-Publication Request: No

Early Publication Request: No



Title

Methods and compositions for the pulmonary delivery insulin of insulin

Preliminary Class

424

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may forego file the application pursuant to 37 CFR 5.15(b).